Endpunktstudien in der Diabetestherapie

The goal of this article is to provide a review of recently published cardiovascular endpoint studies and their consequences for diabetes treatment. Several recent cardiovascular outcomes studies have been published in recent years, demonstrating in patients with advanced disease duration and clinically manifest coronary artery disease that stringent glycemic control results in only a limited reduction of cardiovascular events. In addition, various safety studies have demonstrated the cardiovascular safety of various substances, e.g., DPP-4 inhibitors (DPP: dipeptidyl peptidase). At the same time, some substances, e.g., SGLT?2 inhibitors (SGLT?2: sodium-dependent glucose transporter 2) or certain GLP-1 analogs (GLP-1: glucagon-like peptide 1), were found to reduce the number of cardiovascular events in patients with diabetes and high cardiovascular risk, so that these drugs are increasingly included in the guideline for diabetes treatment. This review summarizes the current data and illustrates the clinical consequences of these findings.